SCYNEXIS, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
SCYNEXIS, Inc. (SCYX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $186.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-10
- SCYNEXIS, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $95.00K, a 20.25% increase year-over-year.
- SCYNEXIS, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $91.00K, a 18.18% increase year-over-year.
- SCYNEXIS, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $87.00K, a 22.54% increase year-over-year.
- SCYNEXIS, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $83.00K, a 18.57% increase year-over-year.
- SCYNEXIS, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $326.00K, a 19.85% increase from fiscal 2024.
- SCYNEXIS, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $272.00K, a 18.26% increase from fiscal 2023.
- SCYNEXIS, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $230.00K, a 11.11% increase from fiscal 2022.
- SCYNEXIS, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $207.00K, a 4.55% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $95.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $186.00K 10-Q · filed 2026-08-10 | $273.00K derived: sum of 3 quarters · filed 2026-08-10 | $356.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $91.00K 10-Q · filed 2026-05-11 | $178.00K derived: sum of 2 quarters · filed 2026-05-11 | $261.00K derived: sum of 3 quarters · filed 2026-05-11 | $340.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $170.00K derived: sum of 2 quarters · filed 2026-03-04 | $249.00K derived: sum of 3 quarters · filed 2026-08-10 | $326.00K 10-K · filed 2026-03-04 |
| 2025-09-30 | $83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $162.00K derived: sum of 2 quarters · filed 2026-08-10 | $239.00K 10-Q · filed 2025-11-05 | $310.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $79.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $156.00K 10-Q · filed 2026-08-10 | $227.00K derived: sum of 3 quarters · filed 2026-08-10 | $297.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $77.00K 10-Q · filed 2026-05-11 | $148.00K derived: sum of 2 quarters · filed 2026-05-11 | $218.00K derived: sum of 3 quarters · filed 2026-05-11 | $285.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $141.00K derived: sum of 2 quarters · filed 2026-03-04 | $208.00K derived: sum of 3 quarters · filed 2026-03-04 | $272.00K 10-K · filed 2026-03-04 |
| 2024-09-30 | $70.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $137.00K derived: sum of 2 quarters · filed 2025-11-05 | $201.00K 10-Q · filed 2025-11-05 | $262.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $131.00K 10-Q · filed 2025-08-13 | $192.00K derived: sum of 3 quarters · filed 2025-08-13 | $251.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $64.00K 10-Q · filed 2025-05-15 | $125.00K derived: sum of 2 quarters · filed 2025-05-15 | $184.00K derived: sum of 3 quarters · filed 2025-05-15 | $240.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $120.00K derived: sum of 2 quarters · filed 2025-03-12 | $176.00K derived: sum of 3 quarters · filed 2025-03-12 | $230.00K 10-K · filed 2025-03-12 |
| 2023-09-30 | $59.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $115.00K derived: sum of 2 quarters · filed 2024-11-06 | $169.00K 10-Q · filed 2024-11-06 | $221.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $56.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $110.00K 10-Q · filed 2024-08-08 | $162.00K derived: sum of 3 quarters · filed 2024-08-08 | $213.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $54.00K 10-Q · filed 2024-05-08 | $106.00K derived: sum of 2 quarters · filed 2024-05-08 | $157.00K derived: sum of 3 quarters · filed 2024-05-08 | $209.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $52.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $103.00K derived: sum of 2 quarters · filed 2024-03-28 | $155.00K derived: sum of 3 quarters · filed 2024-03-28 | $207.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $103.00K derived: sum of 2 quarters · filed 2023-11-13 | $155.00K 10-Q · filed 2023-11-13 | $204.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $52.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $104.00K 10-Q · filed 2023-08-14 | $153.00K derived: sum of 3 quarters · filed 2023-08-14 | $202.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $52.00K 10-Q · filed 2023-05-10 | $101.00K derived: sum of 2 quarters · filed 2023-05-10 | $150.00K derived: sum of 3 quarters · filed 2023-05-10 | $201.00K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $98.00K derived: sum of 2 quarters · filed 2023-03-31 | $149.00K derived: sum of 3 quarters · filed 2023-03-31 | $198.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $100.00K derived: sum of 2 quarters · filed 2022-11-09 | $149.00K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $100.00K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $49.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |